| Company Name: |
SHANGHAI ZZBIO CO., LTD.
|
| Tel: |
021-58979353 13391016096 |
| Email: |
tech@zzbioco.com |
| Products Intro: |
Product Name:2H6]-Sotalol
CAS:1246912-17-3
Package:1mg
|
| Company Name: |
TLC Pharmaceutical Standards Ltd.
|
| Tel: |
18012923235 18012923235 |
| Email: |
chinasales04@tlcstandards.com.cn |
| Products Intro: |
Product Name:Sotalol-d6
CAS:1246912-17-3
Purity:95%+ HPLC Package:10mg;25mg;50mg;100mg
|
|
| | [2H6]-Sotalol Basic information |
| | [2H6]-Sotalol Chemical Properties |
| | [2H6]-Sotalol Usage And Synthesis |
| Uses | Sotalol-d6 is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Marta Reyes-Corral, et al. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019 Apr;369(1):152-162. DOI:10.1124/jpet.118.254375
[3] Xiaomei Li, et al. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. Pediatr Cardiol. 2017 Oct;38(7):1450-1455. DOI:10.1007/s00246-017-1683-9
[4] Kinga K Borowicz-Reutt, et al. Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.Pharmacol Rep. 2021 Apr;73(2):516-524. DOI:10.1007/s43440-020-00210-2 |
| | [2H6]-Sotalol Preparation Products And Raw materials |
|